Clinical application of mizoribine in minimizing virus infection risk in renal graft recipients
- VernacularTitle:咪唑立宾在肾移植术后的应用
- Author:
Yeyong QIAN
;
Bingyi SHI
;
Jianhua AO
- Publication Type:Journal Article
- Keywords:
Immunosuppressive agents;
Kidney transplantation
- From:
Chinese Journal of Organ Transplantation
2005;0(12):-
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the clinical application of mizoribine (MZR) in minimizing virus infection risk in renal transplant patients. Methods Four transplantation centers in Beijing participated in this clinical trial, and 112 primary cadaveric renal allograft recipients were enrolled. MZR in combination with CsA and corticosteroids was used for the prevention of acute rejection (AR). The biochemical data were observed and the infections of 7 different viruses were monitored and recorded. Results All patients were followed up for 12-20 months (average 15. 5 months). The patient/graft survival rate was 96% and the morbidity of AR was 11.6%. All ARs were converted. The major side effect was hyperuricimia, which could be controlled without withdrawal of MZR. The morbidity of CMV infection was 11.6% and no CMV diseases occurred. Only one case experienced adenovirus infection. Conclusions MZR is a safe and effective immunosuppressants. Hyperuricimia should be controlled after operation. The morbidity of virus infections was relatively lowered.
